A Phase 2 Clinical Trial of AR1004 in Patients with Mild Cognitive Impairment

Fred Kim, Tianyang Xi, Jai Jun Choung, Eunjung Jeon, Gesun Choi · 2025

Read A Phase 2 Clinical Trial of AR1004 in Patients with Mild Cognitive Impairment by Fred Kim, Tianyang Xi, Jai Jun Choung, Eunjung Jeon, Gesun Choi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712956.txt.

Description

Mild cognitive impairment means thinking skills have slipped beyond normal aging, though daily life still goes on. Fred Kim, Tianyang Xi, Jai Jun Choung, Eunjung Jeon, and Gesun Choi described a phase 2 trial in 2025 of a traditional Korean herbal product, AR1004, for that condition. In mouse studies the product eased cognitive problems and brain inflammation, which motivated a human test.

The trial in South Korea will enroll up to one hundred adults aged fifty-five to eighty, confirmed by cognitive tests and a blood marker. Half will take the product and half a placebo, twice daily for twenty-four weeks. Thinking scores, brain-related blood markers, and safety will be tracked, with results expected in 2026.

Catalog record

CREATORFred Kim, Tianyang Xi, Jai Jun Choung, Eunjung Jeon, Gesun Choi
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11712956

Browse the full library · About the Tower of Babel